Recommended usage and dosage of Romiplostim

Romiplostim (Romiplostim) is a recombinant humanized thrombopoietin receptor agonist (TPO-RA), mainly used to treat patients with chronic immune thrombocytopenia (ITP), especially for patients with poor response to corticosteroids, immunoglobulins or splenectomy. As a biological agent, romigrastim promotes platelet production by stimulating the maturation and proliferation of megakaryocytes in the bone marrow, and has shown good clinical efficacy and tolerability. In order to achieve the best therapeutic effect, it is important to correctly understand its recommended usage and dosage.

1. Administration method and initial dose

Romiplostim is a subcutaneous injection preparation, usually injected once a week. The recommended starting dose is 1microgram/kg of body weight, injected once a week. The dosage should be adjusted based on the patient's platelet count that week, with the goal of maintaining the platelet count above 50×10⁹/L , but not exceeding 200×10⁹/L, thereby reducing the risk of bleeding and avoiding the risk of thrombosis caused by excessive platelet elevation.

The initial treatment phase is usually injected by professional medical personnel, and the dosage is monitored and adjusted based on weekly blood routine results. Patient weight needs to be accurately recorded and used as the basis for weekly dose calculations.

2. Principles of dose adjustment

The dose of romiplostim should be adjusted weekly according to the patient's platelet response, and can be increased or decreased by 1microgram/kg each time, The maximum dose should not exceed 10mcg/kg of body weight/weeks. If the platelet count is below 50 for two consecutive weeks, the dose should be increased Dosage; if it is higher than 200×10⁹/L, the dose should be reduced or the medication should be suspended. It should be noted that the magnitude and frequency of dose adjustments need to be cautious to avoid excessive platelet fluctuations, especially in the early stages of treatment.

In some patients, it may take longer to respond to treatment due to individual differences. Therefore, clinicians usually recommend continuous medication for at least 4 weeks, and decide whether to continue or adjust the treatment strategy based on platelet changes.

3. Indications for maintenance treatment and discontinuation

After the platelet count reaches the target range and stabilizes, doctors may gradually look for a maintenance dose, which is the lowest possible dose to maintain effective platelet levels. Some patients can maintain a lower dose for a long time, such as 1～3micrograms/kg/weeks, and it continues to be effective. During maintenance treatment, routine blood tests still need to be checked regularly to ensure that platelets are within a safe range.

If the patient's platelet level continues to be stable above the normal range and does not decline significantly after discontinuation of medication, an attempt can be made to gradually reduce the frequency of medication until complete discontinuation of medication. But this must be done under strict supervision by doctors. Once platelets drop again, the treatment plan should be re-evaluated.

4. Special groups and precautions

When using romigrastim in patients with hepatic or renal insufficiency, special attention needs to be paid to drug metabolism. Although its metabolism is mainly processed by the reticuloendothelial system, individual differences may lead to large changes in drug efficacy. In addition, there are insufficient studies demonstrating the safety of romiplostim in pregnant or breastfeeding women, so it should be used with caution after weighing the risks and benefits.

The use of romiplostim in children must be strictly in accordance with the doctor's instructions, because their weight and metabolism are significantly different from adults, and the dosage calculation needs to be more accurate. Romigrastim has also been approved for use in pediatric ITP patients, but the treatment goals are similar to those in adults, which is to reduce the risk of bleeding rather than restore platelets to normal values.

Romiplostim is an effective drug for the treatment of chronic immune thrombocytopenia. It is recommended to be used as a subcutaneous injection once a week. The initial dose is 1microgram/kg. The dose is gradually adjusted according to the patient's platelet response, with the goal of maintaining platelets at 50×10⁹/L to 200×10⁹/L. Blood routine needs to be closely monitored during maintenance treatment, and the dosage should not be changed at will. Discontinuation must be carefully evaluated and the dose may be gradually reduced if necessary. During use, doctor's guidance and patient cooperation are equally important to ensure safe medication and achieve the best therapeutic effect.

Reference: https://en.wikipedia.org/wiki/Romiplostim